Lightheadedness and vertigo pathophysiology

Revision as of 01:35, 29 May 2013 by Saumya Easaw (talk | contribs)
Jump to navigation Jump to search

Lightheadedness and vertigo Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lightheadedness and Vertigo from Other Symptoms

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lightheadedness and vertigo pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

[1]

American Roentgen Ray Society Images of Lightheadedness and vertigo pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onLightheadedness and vertigo pathophysiology

CDC on Lightheadedness and vertigo pathophysiology

and vertigo pathophysiology in the news

Blogs on Lightheadedness and vertigo pathophysiology

Directions to Hospitals Treating Lightheadedness and vertigo

Risk calculators and risk factors for Lightheadedness and vertigo pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]

Overview

Vertigo is usually associated with a problem in the inner ear balance mechanisms (vestibular system), in the brain, or with the nerve connections between these two organs. Vertigo-like symptoms may also appear as paraneoplastic syndrome (PNS) in the form of opsoclonus myoclonus syndrome, a multi-faceted neurological disorder associated with many forms of incipient cancer lesions or virus. If conventional therapies fail, consult with a neuro-oncologist familiar with PNS.

Pathophysiology

The neurochemistry of vertigo includes 6 primary neurotransmitters that have been identified between the 3-neuron arc that drives the vestibulo-ocular reflex(VOR). Many others play more minor roles.

Three neurotransmitters that work peripherally and centrally include glutamate, acetylcholine, and GABA.

  • Glutamate maintains the resting discharge of the central vestibular neurons, and may modulate synaptic transmission in all 3 neurons of the VOR arc.
  • Acetylcholine appears to function as an excitatory neurotransmitter in both the peripheral and central synapses.
  • GABA is thought to be inhibitory for the commissures of the medial vestibular nucleus, the connections between the cerebellar Purkinje cells and the lateral vestibular nucleus, and the vertical VOR.

Three other neurotransmitters work centrally.

  • Dopamine may accelerate vestibular compensation.
  • Norepinephrine modulates the intensity of central reactions to vestibular stimulation and facilitates compensation.
  • Histamine is present only centrally, but its role is unclear. It is known that centrally acting antihistamines modulate the symptoms of motion sickness.

The neurochemistry of emesis overlaps with the neurochemistry of motion sickness and vertigo. Acetylcholine, histamine, and dopamine are excitatory neurotransmitters, working centrally on the control of emesis. GABA inhibits central emesis reflexes. Serotonin is involved in central and peripheral control of emesis but has little influence on vertigo and motion sickness.

References

Template:WikiDoc Sources